Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors

SpringerPlus

Volumn 3, Issue 1, 2014, Pages

  Weide, Rudolf ^a   Feiten, Stefan ^b   Friesenhahn, Vera ^b   Heymanns, Jochen ^a   Kleboth, Kristina ^b   Thomalla, Jörg ^a   van Roye, Christoph ^a   Köppler, Hubert ^a  

^a Praxisklinik für Hämatologie und Onkologie ^*  (Germany)

^b Institut fur Versorgungsforschung in der Onkologie   (Germany)

Author keywords

Breast cancer; Metastasis; Outpatient treatment; Overall survival; Retrospective study

Indexed keywords

EID: 84933503161     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-535     Document Type: Article

References (37)

1. Allemani C, Minicozzi P, Berrino F, Bastiaannet E, Gavin A, Galceran J, Ameijide A, Siesling S, Mangone L, Ardanaz E, Hédelin G, Mateos A, Micheli A, Sant M, EUROCARE Working Group: Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000–2002.Int J Cancer 2013, 132:2404–2412. 10.1002/ijc.27895
2. American College of Physicians (ACP): Medical Knowledge Self Assessment Program® (MKSAP®): Hematology and Oncology.http://www.acponline.org/products_services/mksap/16/. Accessed 20 May 2013
3. Arbeitsgemeinschaft Gynäkologische Onkologie (AGO): Leitlinien/Empfehlungen: Mamma Version 13.1.0.http://www.ago-online.de/de/fuer-mediziner/leitlinien/mamma/. Accessed 17 May 2013.
4. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.N Engl J Med 2012, 366:520–529. 10.1056/NEJMoa1109653
5. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP: TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.J Clin Oncol 2012, 30:2615–2623. 10.1200/JCO.2010.34.5579
6. Chia SK, Speers CH, D'yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O'reilly SE, Olivotto IA: The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.Cancer 2007, 110:973–979. 10.1002/cncr.22867
7. Dafni U, Grimani I, Xyrafas A, Eleftheraki AG, Fountzilas G: Fifteen-year trends in metastatic breast cancer survival in Greece.Breast Cancer Res Treat 2010, 119:621–631. 10.1007/s10549-009-0630-8
8. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P: Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.Cancer 2005, 104:1742–1750. 10.1002/cncr.21359
9. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN: Is breast cancer survival improving?Cancer 2004,100(1):44–52. 10.1002/cncr.11859
10. Holleczek B, Arndt V, Stegmaier C, Brenner H: Trends in breast cancer survival in Germany from 1976 to 2008 - A period analysis by age and stage.Cancer Epidemiol 2011,35(5):399–406. 10.1016/j.canep.2011.01.008
11. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP: Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor 2-positive breast cancer.J Clin Oncol 2008, 26:1993–1999. 10.1200/JCO.2007.12.3588
12. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first line treatment: the M77001 study group.J Clin Oncol 2005, 23:4265–4274. 10.1200/JCO.2005.04.173
13. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP: Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.J Natl Cancer Inst 2008, 17:1780–1791.
14. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN: Combination anastrozole and fulvestrant in metastatic breast cancer.N Engl J Med 2012, 367:435–444. 10.1056/NEJMoa1201622
15. Mergenthaler U, Heymanns J, Köppler H, Thomalla J, van Roye C, Schenk J, Weide R: Evaluation of psychosocial distress in patients treated in a community-based oncology group practice in Germany.Ann Oncol 2011, 22:931–938. 10.1093/annonc/mdq455
16. Montemurro F, Rossi V, Geuna E, Valabrega G, Martinello R, Milani A, Aglietta M: Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer.Expert Opin Pharmacother 2012, 13:2143–2156. 10.1517/14656566.2012.725723
17. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.J Clin Oncol 2003, 21:2101–2109. 10.1200/JCO.2003.04.194
18. Murphy CG, Morris PG: Recent advances in novel targeted therapies for Her2-positive breast cancer.Anticancer Drugs 2012, 23:765–776. 10.1097/CAD.0b013e328352d292
19. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.J Clin Oncol 2000, 18:3758–3767.
20. Office for National Statistics (ONS): Cancer survival by cancer network, patients diagnosed in 1996–2009, followed up to 2010.http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-241176. Accessed 25 September 2013
21. Onkopedia: Leitlinien: Brustkrebs der Frau.https://www.dgho-onkopedia.de/de/mein-onkopedia/leitlinien/brustkrebs-der-frau. Accessed 05 May 2014.
22. Robertson JF, Lindemann JP, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Emerson L, Dean A, Ellis MJ: Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized FIRST study.Breast Cancer Res Treat 2012, 136:503–511. 10.1007/s10549-012-2192-4
23. Rugo HS, Olopade O, DeMichele A, van 't Veer L, Buxton M, Hylton N, Yee D, Chien AJ, Wallace A, Lyandres J, Davis S, Sanil A, Berry D, Esserman L, I-SPY 2 Site PI's: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL. Abstract [S5–02] presented at the 36th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas; 2013. 10–14 December 2013
24. Schlesinger-Raab A, Eckel R, Engel J, Sauer H, Löhrs U, Molls M, Hölzel D: Metastasiertes Mammakarzinom: Keine Lebensverlängerung seit 20 Jahren.Dtsch Arztebl 2005, 102:2706–2714.
25. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione C, Tolaney S, Kuzma CS, Pluard TJ, Somlo G, Port E, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis C, Winer EP: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Abstract [S5–01] presented at the 36th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas; 2013. 10–14 December 2013
26. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science 1987, 235:177–182. 10.1126/science.3798106
27. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpress Her2.N Engl J Med 2001, 344:783–792. 10.1056/NEJM200103153441101
28. Statistisches Bundesamt: Todesursachen.https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Gesundheit/Todesursachen/Tabellen/SterbefaelleInsgesamt.html. Accessed 09 May 2014
29. Surveillance, Epidemiology and End Results Program (SEER 18, 2004–2010): SEER Stat Fact Sheets. Breast Cancer.http://seer.cancer.gov/statfacts/html/breast.html#survival. Accessed 09 December 2013.
30. Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J: Pertuzumab, trastuzumab and docetaxel for Her2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol 2013, 14:461–471. 10.1016/S1470-2045(13)70130-X
31. Tai P, Yu E, Vinh-Hung V, Cserni G, Vlastos G: Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries.BMC Cancer 2004, 4:60. 10.1186/1471-2407-4-60
32. Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD, Sparano JA: Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years.Cancer 2013, 119:1140–1148. 10.1002/cncr.27819
33. Tumorregister München: Tumorstatistik: Überleben. C50. Mammakarzinom (Frauen). http://www.tumorregister-muenchen.de/facts/surv/surv_C50f_G.pdf. Accessed 28 August 2013.
34. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, EMILIA Study Group: Trastuzumab emtansine for Her2-positive advanced breast cancer.N Engl J Med 2012, 367:1783–1791. 10.1056/NEJMoa1209124
35. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03–05 study.J Clin Oncol 2009, 27:1999–2006. 10.1200/JCO.2008.19.6618
36. Weide R, Mergenthaler U, Pandorf A, Arndt H, Heymanns J, Thomalla J, Köppler H: Improved survival of patients with metastatic breast cancer in routine care: results of a retrospective study in a community-based oncology group practice 1995–2005.Onkologie 2009, 32:107–113.
37. Weide R, Feiten S, Heymanns J, Thomalla J, van Roye C, Köppler H: Die Behandlung von Patienten mit metastasierten soliden Tumoren in einer onkologischen Schwerpunktpraxis führt zu einem deutlich längeren Gesamtüberleben im Vergleich mit Registerdaten.Dtsch Med Wochenschr 2012,137(S3):S194.